Navigation Links
GeneLink Reports Third Quarter Results
Date:11/18/2010

ORLANDO, Fla., Nov. 18, 2010 /PRNewswire-FirstCall/ -- GeneLink, Inc. (OTCBB: GNLK), a leading consumer genomics biotech company, today reported financial results for the fiscal quarter ended September 30, 2010.

Highlights:

  • Gross Profit Margin Increase of 28%
  • GeneLink named to Deloitte's Technology Fast 500™ for the second year in a row
  • GeneLink announces Private Label Agreement with Helix Life

Gary Beeman, GeneLink's CEO stated, "The third quarter of 2010 continues to reflect the positive impact of the steps initiated in late 2009 to increase our profit margins as margins increased 28% over the comparable quarter -- a significant accomplishment.  Our top line sales were down slightly, due in part to seasonality in our GeneWize market sector and the continuing US economic conditions.  We were pleased that GeneLink was honored with its second Deloitte's Technology Fast 500™ award as the 62nd fastest growing company in North America in 2009, 17th fastest in the Biotechnology/Pharmaceutical sector.  We announced our 'Powered by GeneLink' private label DNA technology licensing program with health and wellness products provider HelixLife  (www.HelixLife.com) in the third quarter.   GeneLink also announced new 'youth' products for our nutritional and skin care lines which will now allow us to serve the important and influential 12-18 year-old market sector, giving us the ability to now serve entire families through our GeneWize direct selling channel and also HelixLife.  We expect these and other initiatives to contribute to our top-line growth going forward.  The combination of fundamental profit improvement and increasing and diversified revenue opportunities globally is our strategy for shareholder value."  

Dr. Bernard Kasten, GeneLink's Executive Chairman added, "I am pleased to see GeneLink focusing on its core competitive strengths again.  In the third quarter our Scientific Advisory Board and Management Team has been focused on R&D, product development, infrastructure expansion and continued leadership in regulatory compliance and quality.  As the pioneer in genetically-guided nutrition and skin care, GeneLink continues to focus on strengthening our leadership position and leading the growth in consumer genetics."

About GeneLink Biosciences, Inc.:

GeneLink is a 16-year old leading biosciences company specializing in consumer genomics. GeneLink's patented technologies include proprietary DNA test assessments linked to personalized health, beauty and wellness applications and products. Its DNA assessments provide information that enables the customization of nutritional and skincare products designed and manufactured to fulfill each individual consumer's wellness needs. For more information visit www.genelinkbio.com.

This release contains certain forward-looking statements within the meaning of section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. With the exception of historical information contained herein, the matters discussed in the press release involve risk and uncertainties. Actual results could differ materially from those expressed in any forward-looking statement. GeneLink disclaims any intention or obligation to revise any forward-looking statements, whether as a result of new information, future developments or otherwise.


'/>"/>
SOURCE GeneLink, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. GeneLink BioSciences, Inc. Ranked 62nd Fastest Growing Company in North America on Deloittes 2010 Technology Fast 500™
2. GeneLink Announces HelixLife Private Label Distribution Agreement
3. GeneLink Reports First Quarter Gains
4. David L. Macdonald Appointed CEO of GeneLink BioSciences, Inc.
5. Imagenetix, Inc. Reports Second Quarter 2011 Results
6. Transgenomic Reports Third Quarter Financial Results
7. Tiens Biotech Group (USA) Reports Third Quarter and Nine-Month Results
8. Palatin Technologies, Inc. Reports First Quarter Fiscal Year 2011 Results; Teleconference and Webcast to be held on November 16, 2010
9. Celsion Reports Third Quarter 2010 Financial Results and Provides Business Update
10. Dyadic International Reports 2010 Third Quarter Financial Results
11. PharmAthene Reports Third Quarter 2010 Financial and Operational Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/21/2017)... 2017 Interpace Diagnostics Group, Inc. (NASDAQ: ... clinically useful molecular diagnostic tests and pathology services, ... securities purchase agreement with three  institutional investors to ... stock in a registered direct offering.  In a ... sell to the same investors warrants to purchase ...
(Date:1/21/2017)... , Jan. 20, 2017 Aratana Therapeutics, ... company focused on the licensing, development and commercialization of ... Pharm,s Best Company in North America ... the award based on the FDA approval ... (grapiprant tablets), ENTYCE ® (capromorelin oral solution) and ...
(Date:1/20/2017)... ... , ... The two newest companies to join the University City Science Center’s ... from The Wistar Institute, and Sanguis, launched by a trio of students from the ... Vironika is developing a treatment for a chronic viral infection and its associated diseases, ...
(Date:1/20/2017)... Ginkgo Bioworks, the organism company, announced ... the synthesis and assembly of DNA. The acquisition ... synthetic DNA into Ginkgo,s automated organism engineering foundries, ... of new organism designs for application across a ... founded to significantly increase the world,s capacity to ...
Breaking Biology Technology:
(Date:12/19/2016)... , 19 de diciembre de 2016  Mosaic Biomedicals SL ... desarrollo acelerado de MSC-1, un anticuerpo humanizado que se espera comenzar ... 2017, con múltiples sitios previstos a lo largo de Europa y ... MSC-1 es ... inhibidor de leucemia (LIF), una citoquina pleiotrópica que se sobreexpresa en ...
(Date:12/15/2016)...   WaferGen Bio-systems, Inc. (NASDAQ: ... today that on December 13, 2016, it received a ... Stock Market LLC which acknowledged that, as of December ... stock had been at $1.00 or greater for ten ... Listing Rule 5550(a)(2) of the Nasdaq Stock Market. ...
(Date:12/12/2016)...  Researchers at Trinity College, Dublin, are opening ... the material with Silly Putty. The mixture (known as ... to sense pulse, blood pressure, respiration, and even ... The research team,s findings were published Thursday ... http://science.sciencemag.org/content/354/6317/1257 ...
Breaking Biology News(10 mins):